Andrea Tan
Stock Analyst at Goldman Sachs
(1.90)
# 3,201
Out of 5,141 analysts
53
Total ratings
39.02%
Success rate
-7.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrea Tan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech | Maintains: Buy | $206 → $327 | $261.80 | +24.90% | 2 | Feb 2, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Neutral | $50 → $85 | $63.59 | +33.67% | 3 | Jan 7, 2026 | |
| INSM Insmed | Maintains: Buy | $258 → $225 | $164.91 | +36.44% | 15 | Dec 18, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $16 → $8 | $2.87 | +178.75% | 7 | May 12, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Neutral | $46 → $51 | $66.61 | -23.43% | 4 | May 5, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $39 → $27 | $11.78 | +129.20% | 6 | Mar 25, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Neutral | $23 → $6 | $5.32 | +12.78% | 5 | Jul 1, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Sell | $3 → $2 | $4.13 | -51.57% | 3 | Jun 5, 2024 | |
| KOD Kodiak Sciences | Reinstates: Sell | $2 | $25.28 | -92.09% | 1 | Dec 11, 2023 | |
| ABCL AbCellera Biologics | Maintains: Buy | $27 → $24 | $3.04 | +689.47% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $4 | $1.46 | +173.97% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $375 | $435.01 | -13.80% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $80 | $13.55 | +490.41% | 2 | May 24, 2022 |
Krystal Biotech
Feb 2, 2026
Maintains: Buy
Price Target: $206 → $327
Current: $261.80
Upside: +24.90%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Neutral
Price Target: $50 → $85
Current: $63.59
Upside: +33.67%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $258 → $225
Current: $164.91
Upside: +36.44%
Iovance Biotherapeutics
May 12, 2025
Maintains: Buy
Price Target: $16 → $8
Current: $2.87
Upside: +178.75%
Tarsus Pharmaceuticals
May 5, 2025
Maintains: Neutral
Price Target: $46 → $51
Current: $66.61
Upside: -23.43%
Day One Biopharmaceuticals
Mar 25, 2025
Maintains: Buy
Price Target: $39 → $27
Current: $11.78
Upside: +129.20%
Sagimet Biosciences
Jul 1, 2024
Maintains: Neutral
Price Target: $23 → $6
Current: $5.32
Upside: +12.78%
Relmada Therapeutics
Jun 5, 2024
Downgrades: Sell
Price Target: $3 → $2
Current: $4.13
Upside: -51.57%
Kodiak Sciences
Dec 11, 2023
Reinstates: Sell
Price Target: $2
Current: $25.28
Upside: -92.09%
AbCellera Biologics
Aug 4, 2023
Maintains: Buy
Price Target: $27 → $24
Current: $3.04
Upside: +689.47%
Jan 9, 2023
Maintains: Sell
Price Target: $10 → $4
Current: $1.46
Upside: +173.97%
Dec 20, 2022
Maintains: Buy
Price Target: $178 → $375
Current: $435.01
Upside: -13.80%
May 24, 2022
Maintains: Neutral
Price Target: $120 → $80
Current: $13.55
Upside: +490.41%